By: Sean Whooley
Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates.


Sean Whooley is an Assistant Editor at MassDevice. He specializes in medicine and healthcare, particularly focusing on healthcare technology, medical equipment innovations, and corporate finance within the medical sector. Sean's work has been featured in various outlets, including NewsBreak, The Robot Report, and Drug Discovery & Development.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston


Not enough data
Sean Whooley's articles predominantly focus on healthcare and pharmaceuticals, with a specific emphasis on medical technology, FDA approvals, medical devices, and the pharmaceutical industry. His coverage heavily features press releases and private sector announcements.
To effectively reach out to Sean, consider providing access to exclusive interviews or insights from key figures within the healthcare and pharmaceutical sectors. Additionally, offering in-depth analysis of new technologies or regulatory developments in the medical field could be particularly appealing to him. Given his interest in scientific themes as well, pitches related to cutting-edge research or technological advancements may also capture his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .